Literature DB >> 11144755

Chemical mapping of anxiety in the brain of healthy humans: an in vivo 1H-MRS study on the effects of sex, age, and brain region.

I D Grachev1, A V Apkarian.   

Abstract

We recently presented results in an in vivo study of human brain chemistry in 'physiologic' anxiety, i.e., the anxiety of normal everyday life. Normal subjects with high anxiety demonstrated increased concentration of chemicals in orbital frontal cortex (OFC) as compared to lower anxiety. In a separate study of aging we demonstrated a decrease of total chemical concentration in OFC of middle-aged subjects, as compared with younger age. This brain region also showed gender dependence; men demonstrating decreased chemical concentration compared to women. We hypothesized that these sex- and age-dependent differences in OFC chemistry changes are a result of anxiety effects on this brain region. In the present study we examined these sex- and age-differential regional brain chemistry changes (as identified by localized in vivo proton magnetic resonance spectroscopy [1H-MRS]) in relation to the state-trait-anxiety (as measured by the State-Trait Anxiety Inventory) in 35 healthy subjects. The concentrations for all nine chemicals of 1H-MRS spectra were measured relative to creatine across multiple brain regions, including OFC in the left hemisphere. Analysis of variance showed anxiety-specific effects on chemical concentration changes in OFC, which were different for both sexes and age groups. Male subjects showed larger effect of anxiety on OFC chemistry as compared to females when the same sex high-anxiety subjects were compared to lower anxiety. Similarly, middle-aged subjects showed larger effect of anxiety on OFC chemistry as compared to younger age when the same age subjects with high anxiety were compared to lower anxiety. Largest effect of anxiety on OFC chemistry was due to changes of N-Acetyl aspartate. The results indicate that the state-trait anxiety has sex- and age-differential patterns on OFC chemistry in healthy humans, providing new information about the neurobiological roots of anxiety.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144755      PMCID: PMC6871936          DOI: 10.1002/1097-0193(200012)11:4<261::aid-hbm30>3.0.co;2-6

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  48 in total

1.  Aging alters regional multichemical profile of the human brain: an in vivo 1H-MRS study of young versus middle-aged subjects.

Authors:  I D Grachev; A V Apkarian
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

Review 2.  Regional brain function, emotion and disorders of emotion.

Authors:  R J Davidson; H Abercrombie; J B Nitschke; K Putnam
Journal:  Curr Opin Neurobiol       Date:  1999-04       Impact factor: 6.627

Review 3.  The functional anatomy, neurochemistry, and pharmacology of anxiety.

Authors:  P T Ninan
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

4.  A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery.

Authors:  S L Rauch; B A van der Kolk; R E Fisler; N M Alpert; S P Orr; C R Savage; A J Fischman; M A Jenike; R K Pitman
Journal:  Arch Gen Psychiatry       Date:  1996-05

5.  Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers.

Authors:  C Benkelfat; J Bradwejn; E Meyer; M Ellenbogen; S Milot; A Gjedde; A Evans
Journal:  Am J Psychiatry       Date:  1995-08       Impact factor: 18.112

6.  Generalized anxiety disorder in women. A population-based twin study.

Authors:  K S Kendler; M C Neale; R C Kessler; A C Heath; L J Eaves
Journal:  Arch Gen Psychiatry       Date:  1992-04

Review 7.  Epidemiology and comorbidity of anxiety disorders in later life: implications for treatment.

Authors:  A J Flint
Journal:  Clin Neurosci       Date:  1997

8.  Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues.

Authors:  F Crestani; M Lorez; K Baer; C Essrich; D Benke; J P Laurent; C Belzung; J M Fritschy; B Lüscher; H Mohler
Journal:  Nat Neurosci       Date:  1999-09       Impact factor: 24.884

9.  The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women.

Authors:  B B Sherwin
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958

10.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01
View more
  5 in total

1.  Structural evidence for involvement of a left amygdala-orbitofrontal network in subclinical anxiety.

Authors:  Karen Blackmon; William B Barr; Chad Carlson; Orrin Devinsky; Jonathan DuBois; Daniel Pogash; Brian T Quinn; Ruben Kuzniecky; Eric Halgren; Thomas Thesen
Journal:  Psychiatry Res       Date:  2011-07-30       Impact factor: 3.222

2.  Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.

Authors:  N L Mason; K P C Kuypers; F Müller; J Reckweg; D H Y Tse; S W Toennes; N R P W Hutten; J F A Jansen; P Stiers; A Feilding; J G Ramaekers
Journal:  Neuropsychopharmacology       Date:  2020-05-23       Impact factor: 7.853

Review 3.  Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.

Authors:  Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

Review 4.  1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Authors:  Sylvana Vilca-Melendez; Malin V Uthaug; Julian L Griffin
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

Review 5.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.